Data Sharing as Part of the Normal Scientific Process: A View from the Pharmaceutical Industry
- PMID: 26731493
- PMCID: PMC4701406
- DOI: 10.1371/journal.pmed.1001936
Data Sharing as Part of the Normal Scientific Process: A View from the Pharmaceutical Industry
Abstract
Reflecting on the WHO consultation on developing global norms for sharing data and results during public health emergencies, Patrick Vallance and colleagues argue that there are significant benefits to the principle of data sharing.
Conflict of interest statement
We have read the journal's policy and have the following conflicts: PV is a President at GlaxoSmithKline and holds stock or stock options in GlaxoSmithKline. AF is Head of Medical Policy at GlaxoSmithKline and holds stock or stock options in GlaxoSmithKline. MS is Chief Medical Officer at GlaxoSmithKline and holds stock or stock options in GlaxoSmithKline. PV is a member of the Editorial Board of
Comment on
-
Developing Global Norms for Sharing Data and Results during Public Health Emergencies.PLoS Med. 2016 Jan 5;13(1):e1001935. doi: 10.1371/journal.pmed.1001935. eCollection 2016 Jan. PLoS Med. 2016. PMID: 26731342 Free PMC article. Review.
References
-
- The Royal Society. Science as an open enterprise. https://royalsociety.org/~/media/policy/projects/sape/2012-06-20-saoe.pdf
-
- Institute of Medicine. Sharing clinical trial data: maximizing benefit, minimizing risk. http://iom.nationalacademies.org/Reports/2015/Sharing-Clinical-Trial-Dat...
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
